Showing results (171-180 of 227) with videos related to
Sort By:
Pageof 23
Journal of Neuro-Oncology|November 7, 2019
Correction to: Efficacy of initial temozolomide for high‑risk low grade gliomas in a phase II AINO (Italian Association for Neuro‑Oncology) study: a post‑hoc analysis within molecular subgroups of WHO 2016Roberta Rudà, Alessia Pellerino, Andrea Pace, et al.Journal of Experimental & Clinical Cancer Research : CR|August 29, 2016
Brain stereotactic biopsy flow cytometry for central nervous system lymphoma characterization: advantages and pitfallsIole Cordone, Serena Masi, Mariantonia Carosi, et al.Journal of Neuro-Oncology|September 27, 2019
Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016Roberta Rudà, Alessia Pellerino, Andrea Pace, et al.Medicina (Kaunas, Lithuania)|July 29, 2023
Does Surgical Approach Influence Complication Rate of Hip Hemiarthroplasty for Femoral Neck Fractures? A Literature Review and Meta-AnalysisMatteo Filippini, Marta Bortoli, Andrea Montanari, et al.BMC Cancer|April 2, 2009
Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylationAlessandra Fabi, Giulio Metro, Michelangelo Russillo, et al.Journal of Neuro-Oncology|April 22, 2014
IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapyGiuseppe Minniti, Claudia Scaringi, Antonella Arcella, et al.International Journal of Molecular Sciences|June 10, 2023
Investigating the Inhibition of FTSJ1, a Tryptophan tRNA-Specific 2'-O-Methyltransferase by NV TRIDs, as a Mechanism of Readthrough in Nonsense Mutated CFTRPietro Salvatore Carollo, Marco Tutone, Giulia Culletta, et al.Journal of Neurology|February 20, 2021
Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasibile? Results from AINO study (Italian Association for Neuro-Oncology)Veronica Villani, Elena Anghileri, Luca Prosperini, et al.Cancer Chemotherapy and Pharmacology|October 23, 2009
Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiformeGiulio Metro, Alessandra Fabi, Maria A Mirri, et al.Future Oncology (London, England)|January 19, 2019
Comorbidities in elderly patients with glioblastoma: a field-practice studyVeronica Villani, Antonio Tanzilli, Stefano M Telera, et al.Pageof 23